PR Newswire PharmaOriginal article
The U.S. FDA grants orphan drug designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for treatment of endogenous Cushing's syndrome
RegulatoryapprovedasedebartPositive
AI Analysis
Summary
Lundbeck's asedebart, an anti-ACTH monoclonal antibody, received FDA Orphan Drug Designation for endogenous Cushing's syndrome treatment. This designation facilitates development and provides regulatory incentives for treating the rare endocrine disorder.
Outcome Details
Orphan Drug Designation granted by U.S. FDA
Importance:6/10
Sentiment:
0.80
orphan drugFDA designationmonoclonal antibodyrare diseaseendocrine disorder
Related Companies
Read the original article
Published by PR Newswire Pharma on September 11, 2026 8:24 AM